NCT02338349 2022-08-18
A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer
Stemline Therapeutics, Inc.
Phase 1 Completed
Stemline Therapeutics, Inc.
Stemline Therapeutics, Inc.